FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.22-SNAPSHOT  |  FHIR Version n/a  User: [n/a]

716017002: Idarucizumab (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2016. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3304446011 Idarucizumab (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
3304447019 Idarucizumab en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
57591000195111 idarucizumab it Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
817281000172110 idarucizumab fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module
72121000195115 Idarucizumab de Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Idarucizumab (substance) Is a Monoclonal antibody true Inferred relationship Some
Idarucizumab (substance) Is a Antidote (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing idarucizumab (medicinal product) The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Idarucizumab (substance) Inferred relationship Some 1
Idarucizumab-containing product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Idarucizumab (substance) Inferred relationship Some 1
Idarucizumab only product The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Idarucizumab (substance) Inferred relationship Some 1
Idarucizumab only product in parenteral dose form The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. True Idarucizumab (substance) Inferred relationship Some 1
Product containing precisely idarucizumab 50 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). True Idarucizumab (substance) Inferred relationship Some 1
Product containing precisely idarucizumab 50 milligram/1 milliliter conventional release solution for infusion and/or injection (clinical drug) This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. True Idarucizumab (substance) Inferred relationship Some 1

Reference Sets

GB English

US English

Back to Start